ESPAUR 2025: antibacterial resistance and the emergence of Candidozyma auris in England

The latest ESPAUR report (2024–2025) paints a sobering picture of AMR in England. While prescribing practices have improved in some areas, the resistant infections are increasing, and new threats like Candidozyma auris are emerging.

Continue reading →

Farewell 2024 – ESPAUR helps us to set priorities for 2025

As we bid farewell to 2024, a time for reflection, objective setting, and the odd new years resolution to break early in 2025. The latest ESPAUR report was published a few months ago, and helps us to set some priorities for 2025 and beyond. As ever, there’s a mixture of good news and bad news in the report, but mostly I’m grateful that we have sufficient data and co-ordination to give us this level of detail about the current and emerging threats related to HCAI and AMR in the UK.

Continue reading →